Literature DB >> 22383229

Natalizumab-associated central nervous system lymphoma?--another patient.

Mike Matzke, Stefanie Schreiber, Erck Elolf, Imke Metz, Christian Mawrin, Hans-Jochen Heinze, Michael Sailer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22383229     DOI： 10.1177/1352458512439336

Source DB:  PubMed          Journal:  Mult Scler        ISSN： 1352-4585            Impact factor:   6.312


× No keyword cloud information.
  4 in total

Review 1.  Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Authors:  Adnan M Subei; Daniel Ontaneda
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749

Review 2.  Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.

Authors:  Justin M Honce; Lidia Nagae; Eric Nyberg
Journal:  Mult Scler Int       Date:  2015-09-21

3.  Successful Management of Natalizumab-Associated Primary Central Nervous System Lymphoma through Autologous Stem Cell Transplant.

Authors:  Karine Moineau-Vallée; Justine Rinfret; My Hanh Luu Hoai; Valérie St-Louis; France Berthelet; Laurent Létourneau-Guillon; Émilie Lemieux-Blanchard; Alexandre Prat; Jean-Philippe Adam
Journal:  Curr Oncol       Date:  2020-12-30       Impact factor: 3.677

4.  The unexpected finding of a hemangioblastoma on the cerebellum of a patient undergoing treatment with natalizumab for multiple sclerosis.

Authors:  Yara Dadalti Fragoso; Joseph Bruno Bidin Brooks; Mateus Reghin Neto
Journal:  Iran J Neurol       Date:  2017-04-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.